Shares of NASDAQ:SMMT opened at $1.18 on Friday. The stock has a market cap of $115.78 million, a price-to-earnings ratio of -1.23 and a beta of 0.99. Summit Therapeutics has a 12-month low of $1.01 and a 12-month high of $8.70. The business’s 50 day moving average is $2.26 and its 200 day moving average is $3.11.
Summit Therapeutics (NASDAQ:SMMT – Get Rating) last announced its earnings results on Thursday, March 17th. The company reported ($0.28) earnings per share (EPS) for the quarter. The company had revenue of $4.84 million for the quarter. Summit Therapeutics had a negative net margin of 493.14% and a negative return on equity of 95.94%.
Summit Therapeutics Company Profile (Get Rating)
Summit Therapeutics Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI.
- Get a free copy of the StockNews.com research report on Summit Therapeutics (SMMT)
- Carvana Insiders Buy Shares But Maybe You Shouldn’t
- Dutch Bros Gets Scalded By Inflation
- The S&P 500 Could Fall Another 28%
- Corning Stock is a Technology Value Play
- Wolverine Worldwide Is Ready To Rebound
Receive News & Ratings for Summit Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.